---
title: "Aprea Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview"
description: "Aprea Therapeutics Inc is anticipated to report a loss of 34 cents per share for the quarter ending September 30, 2025, with a decline in revenue expected. Analysts maintain a \"strong buy\" rating, wit"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/264049725.md"
published_at: "2025-11-03T14:40:19.000Z"
---

# Aprea Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

> Aprea Therapeutics Inc is anticipated to report a loss of 34 cents per share for the quarter ending September 30, 2025, with a decline in revenue expected. Analysts maintain a "strong buy" rating, with no holds or sells. The median 12-month price target is $10.50, representing an 86.7% increase from the last closing price of $1.40. The mean earnings estimate has remained unchanged over the past three months.

-   Aprea Therapeutics Inc is expected to show a fall in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025

-   ​LSEG's mean analyst estimate for Aprea Therapeutics Inc is for a loss of 34 cents per share.
-   The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
-   The mean earnings estimate of analysts was unchanged in the last three months. ​
-   Wall Street's median 12-month price target for Aprea Therapeutics Inc is $10.50, about 86.7% above its last closing price of $1.40

### Related Stocks

- [APRE.US - Aprea Therapeutics](https://longbridge.com/en/quote/APRE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Aprea Therapeutics 的高级癌症试验显示出令人期待的结果，股价大幅上涨 | Aprea Therapeutics 的股价上涨了 16.62%，达到 0.70 美元，此次上涨是由于 APR-1051 的第一阶段试验结果令人鼓舞，该药物是一种用于癌症治疗的 WEE1 激酶抑制剂。试验报告显示一名晚期子宫内膜癌患者出现第 | [Link](https://longbridge.com/en/news/276264904.md) |
| Aprea Therapeutics 在澳大利亚和日本获得了新专利，以增强其全球 DDR 癌症治疗产品组合 | Aprea Therapeutics 在澳大利亚和日本获得了新的专利，增强了其在全球范围内的知识产权，涵盖其 DNA 损伤反应 (DDR) 肿瘤学管线。这些专利于 2025 年获得批准，增强了对 WEE1 和 ATR 项目的保护，预计独占权 | [Link](https://longbridge.com/en/news/275688060.md) |
| 财报、指引皆超预期，“AI 应用热股” Applovin 股价依旧大跌 | 财报显示，AppLovin Q4 营收 16.6 亿美元（+66%）及 EBITDA 利润率（84%）均超预期，但因市场担忧 AI 颠覆及 Meta 竞争，股价盘后大跌。公司 CEO 强硬回应称市场情绪与现实脱节，强调 AI 带来的内容爆发 | [Link](https://longbridge.com/en/news/275682023.md) |
| 新 “次贷危机”？美国 PE 的 “软件业贷款敞口” 比财报显示的更大 | 彭博调查显示，美国七大商业开发公司（BDC）至少将 90 亿美元的软件业贷款归类为其他行业，导致实际软件敞口远超财报披露水平。这种分类混乱掩盖了信贷基金在软件业的高度集中风险。在 AI 颠覆传统软件模式及软件股暴跌的背景下，这一隐形敞口引发 | [Link](https://longbridge.com/en/news/275961330.md) |
| 谷歌 Q4 财报在即！4.1 万亿美元市值面临考测，业绩增长需支撑估值扩张 | Alphabet 正于市值突破 4 万亿美元的历史高位迎来关键财报。市场预期其 AI 驱动的广告与云业务将强劲增长，但焦点已转向可能高达 1400 亿美元的资本开支指引。公司能否用业绩证明其巨额 AI 投资的合理性，将决定其能否避免高估值下 | [Link](https://longbridge.com/en/news/274818876.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.